Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lunsayil 1: spesolimab versus placebo in moderate to severe hidradenitis suppurativa
jRCT2041230016Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Spesolimab (Spevigo) arm with Placebo arm (2 arms). Primary endpoint: Percent change from baseline in draining fistula/tunnel (dT) count at Week 8. Started May 2023; status: completed.
02
Drugs
spesolimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on jRCT2041230016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041230016.